HLA-matched allogeneic anti-CD19 CAR-T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden

作     者：Yue Huang MD Qin Yu PhD Elaine Tan Su Yin MD Guoqing Wei PhD Wenjun Wu PhD Alex H. Chang PhD He Huang PhD Yongxian Hu PhD 

作者机构：Bone Marrow Transplantation Center the First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China Institute of Hematology Zhejiang University Hangzhou China Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy Hangzhou China Zhejiang Laboratory for Systems & Precision Medicine Zhejiang University Medical Center Hangzhou China College of Life Science Zhejiang Chinese Medical University Hangzhou China Cellular Therapy Department Shanghai YaKe Biotechnology Ltd Shanghai China He Huang MD/PhD and Yongxian Hua Bone Marrow Transplantation Center The First Affiliated Hospital School of Medicine Zhejiang University No.79 Qingchun Road Hangzhou China. 

出 版 物：《ImmunoMedicine》 

年 卷 期：2022年第2卷第1期

主　　题：acute lymphoblastic leukemia allogeneic chimeric antigen receptor T cells central nervous system leukemia cytokine release syndrome HLA-matched 

摘      要：The genetically engineered chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR-T cell products in patients with high tumor burden and prior tumor-reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor-derived HLA-matched allogeneic CAR-T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR-T therapy.